Surgalign Completes First Quarter As Pure-Play Spine Company

Surgalign's logo

Surgalign reported 3Q20 orthopedic revenue of USD $27.9 million, -2.7% vs. 3Q19. In its first quarter as a pure-play spine company, Surgalign’s 3Q20 revenues were on par with the prior year. The majority of the $800,000 shortfall relates to changes in revenue recognition procedures for international biologics sales.

The company is...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us